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patients (15%) were lost to follow-up. ??????????? Improvements could 
be made in the documentation of important parts of the history and clinical 
features that identify those patients diagnosed with PID.
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???????????????? Dipeptidyl peptidase-IV (DPP-4) inhibitors are a relatively 
new class of anti-diabetic drugs that have therapeutic potential for management 
of atherosclerosis. Of the numerous DPP4-inhibitors in clinical practice, no 
studies have been conducted to compare their anti-atherosclerotic effects 
despite growing evidence of their usefulness in the high-risk population. 
The aim of the study is to evaluate and grade the anti-atherothrombotic 
effects of DPP-4 inhibitors in subjects with atherosclerosis. ???????? A 
literature search was conducted on MEDLINE and the Cochrane Library 
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‘cytokines’, ‘stroke’, ‘ischaemic heart disease’, ‘hypertension’ and ‘peripheral 
vascular disease’. A mathematical model devised by us was used to 
??????? ???? ???????? ???? ????????????????? ???????? ??? ?????????? ???????????
using protective score (PS). Data were analysed for alogliptin, linagliptin, 
saxagliptin, sitagliptin, and vildagliptin. ???????? Sixty-two published studies 
collected in the search were assessed for relevance to this study. Sitagliptin 
had the highest PS (n=5) while Linagliptin and Saxagliptin yielded the lowest 
PS (n=1). This comparison and scoring system was limited to the data 
collected, which did not investigate all athero-thrombotic factors selected in 
this study. ?????????????????????????????????????????????????????????????????
the other DPP-4 inhibitors in the management of atherosclerosis. Further 
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in atherothrombotic disease. 
???????????????????????????????
?????????????????????????????????????????
????????????????????
??????????????????????????????????????????????????? ?????
Translational Research on Endocrinology and Diabetes (TREAD), College of Medicine and 
Dentistry, James Cook University, Townsville, Queensland
???????????????? Dipeptidyl peptidase-IV (DPP-4) inhibitors are a 
relatively new class of anti-diabetic drugs that have therapeutic potential for 
management of hypercholesterolemia. Of the numerous DPP4-inhibitors 
in clinical practice, no systematic review has been conducted to compare 
their anti-hypercholesterolemic effect, despite growing evidence of their 
usefulness in the high risk population. ???????? A systematic review of 
existing literature investigating cholesterol-lowering effects of DPP4 inhibitors 
was conducted. Published data on DDP-4 inhibitors use for more than six 
months in hypercholesterolemic subjects were sought from MEDLINE, 
PubMed and Google Scholar search of English language literature from 1994 
to 2014 using the key words: ‘DPP-4 inhibitors’, ‘hypercholesterolemia’ 
‘dyslipidemia’ and ‘hyperlipidemia’. ???????? A total of six full-text published 
studies conducted worldwide were included in this systematic review, 
comprising a total of 3968 subjects. Anti-hypercholesterolemic effects range 
between 13.3% reduction in total cholesterol by sitagliptin and vildagliptin, to 
no effect by linagliptin.  Conversely, saxagliptin demonstrated modest anti-
hypercholesterolemic effect. ??????????????????????????????????????????????
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particularly in subjects with diabetes. Further investigations are required to 
????????????????????????????????????????????????????????????????????????????
to elucidate their clinical application in addition to its established anti-diabetic 
effects.
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???????????????? Marine microalgae contain a large variety of bioactive 
substances that can be harnessed for their therapeutic potentials, including 
polyunsaturated fatty acids (PUFA), sterols, carotenoids, pigments, proteins 
and vitamins. A possible implication of these bioactive molecules is to control 
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effects of microalgal diet on behaviour have not been investigated. The aim of 
this study is to examine the effect of microalgal diet on the depression-related 
behavioural consequences of chronic social defeat (CSD) in mice. ???????? 
From the age of 21 days for 11 weeks mice were fed with either (1) control 
normal mouse chow, or  mouse chow containing (2) high concentration of 
saturated fats (high-fat ‘Western diet’; HFD), or (3) microalgal biomass with 
high concentration of PUFAs (including docosahexanoic acid, DHA), or (4) 
de-fatted algal biomass (ALG). Mice were then either subjected to CSD or 
remained undisturbed. Psychomotor activity, anxiety-like behaviour and 
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Y-maze and novel object recognition, respectively, taking advantage of a 
behavioural recognition software, TopScanLite (CleverSystem). ???????? 
CSD induced social avoidance in HFD and DHA mice. ALG feeding prevented 
psychomotor retardation and cognitive impairments induced by CSD but 
HFD and DHA resulted in a worsening of the behavioural consequences 
of CSD. ??????????? Our preliminary results show that certain bioactive 
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in preventing adverse behavioural consequences of chronic psychosocial 
stress in mice and high DHA concentrations should be used with caution.
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???????????????? Many emergency departments (EDs) state-wide use 
emergency pack (EP) systems for discharging patients outside of pharmacy 
hours. Patients receive the EP without counselling from a pharmacist. Not all 
medications have consumer medication information (CMI) pre-supplied. The 
Pharmacy Board of Australia, Pharmaceutical Society of Australia and the 
Society of Hospital Pharmacists Australia all advocate for the provision of CMI. 
Their use is well documented to improve safety, compliance and continuity 
of care. Under these circumstances where a pharmacist is unavailable, a CMI 
is highly recommended. The aim of this study is to review and improve the 
current EP processes across the health district to meet standards held by our 
professional governing bodies. ???????? EP stock holding of four hospitals 
within our health service district was reviewed to determine the percentage 
of EPs that contained CMIs. The current procedure was changed so that 
